50岁及以下乳腺癌女性术前乳腺MRI与生存结局
这项回顾性研究纳入2011年1月至2017年12月在两家三级医院手术的4414例50岁及以下新发单侧乳腺癌女性,采用逆概率治疗加权比较术前MRI组(4118例)与未MRI组(296例)。MRI组5年同侧乳房内复发累积发生率低于未MRI组(1.6% vs 3.3%;sHR 0.49;P=0.04),但总复发无差异证据(sHR 0.70;P=0.15);激素受体阴性患者中MRI组复发更低。
要点
- MRI组5年同侧乳房内复发累积发生率为1.6%,低于未MRI组的3.3%(sHR 0.49;P=0.04)。
- MRI组与未MRI组总复发无差异证据(sHR 0.70;95%CI 0.43–1.13;P=0.15)。
- 激素受体阴性患者中MRI组5年复发累积发生率为8.2%,低于未MRI组的20.7%(sHR 0.40;95%CI 0.19–0.82)。
核心结论
- 术前MRI与50岁及以下乳腺癌患者同侧乳房内复发风险降低相关,激素受体阴性者获益最大。
研究设计与样本
- 回顾性研究,纳入2011年1月至2017年12月两家三级医院4414例50岁及以下新发单侧乳腺癌手术患者,采用逆概率治疗加权平衡MRI组与未MRI组,中位随访7.7年。
诊断标准与关键数值
- 5年同侧乳房内复发累积发生率MRI组1.6% vs 未MRI组3.3%(sHR 0.49;P=0.04);总复发sHR 0.70(95%CI 0.43–1.13;P=0.15);激素受体阴性患者5年复发累积发生率MRI组8.2% vs 未MRI组20.7%(sHR 0.40;95%CI 0.19–0.82;P=0.04),同侧乳房内复发sHR 0.28(95%CI 0.10–0.76);总生存HR 0.62(95%CI 0.26–1.50;P=0.58)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Data on the impact of preoperative MRI on long-term outcomes in young patients with breast cancer are insufficient. Purpose To investigate the associations of preoperative MRI with recurrence and survival outcomes in patients 50 years or younger with newly diagnosed breast cancer, and the impact of hormone receptor status on these associations. Materials and Methods This retrospective study included patients aged 50 years or younger with newly diagnosed unilateral breast cancer who underwent surgery at one of two tertiary hospitals between January 2011 and December 2017. Patients who underwent preoperative MRI (MRI group) were balanced with patients who did not (no-MRI group) using inverse probability of treatment weighting (IPTW). Recurrence and death were compared between the MRI and no-MRI groups using hazard ratios (HRs) with 95% CIs. P values were obtained using Fine and Gray models for recurrence and Cox proportional hazards models for death, both adjusted with IPTW. Patients were followed up for a median of 7.7 years. Results Of the 4414 women included (mean age, 43.2 years ± 5.2 [SD]), 4118 (93.3%) underwent preoperative MRI, and 296 (6.7%) did not. A total of 342 patients (7.7%) experienced recurrence. The 5-year cumulative incidence of ipsilateral in-breast recurrence was lower in the MRI group than in the no-MRI group (1.6% vs 3.3%; subdistribution hazard ratio [sHR], 0.49; P = .04). However, there was no evidence of a difference in total recurrence between the MRI and no-MRI groups (sHR, 0.70 [95% CI: 0.43, 1.13]; P = .15). In patients with hormone receptor-negative cancer, the 5-year cumulative incidence of recurrence was lower in the MRI group than the no-MRI group (8.2% vs 20.7%; sHR, 0.40 [95% CI: 0.19, 0.82]; P = .04), as was the incidence of ipsilateral in-breast recurrence (sHR, 0.28 [95% CI: 0.10, 0.76]). There was no evidence of a difference in overall survival (HR, 0.62 [95% CI: 0.26, 1.50]; P = .58). Conclusion Preoperative MRI was associated with reduced risk of ipsilateral breast cancer recurrence in patients 50 years or younger, with the greatest benefit in those with hormone receptor-negative cancers. © RSNA, 2025 Supplemental material is available for this article.
引用
- Yoen H, Shin HC, Yoon KH, et al. Preoperative Breast MRI and Survival Outcomes in Women 50 Years or Younger with Breast Cancer. Radiology. 2025. PMID: 41117653. doi:10.1148/radiol.250439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。